Table 1.
Effects of inhibitors on CSF-1–induced D2 and myca
| Name of inhibitor | Target(s) | Decrease (D)/increase (In)
|
|
|---|---|---|---|
| On D2 | On c-myc | ||
| FTI-277 | H-ras, N-Ras | D | — |
| GGTI-298 | K-Ras | D | — |
| PP1 | Src family kinases | D | — |
| Lithium | GSK-3β | — | — |
| Rottlerin | PKCδ/CaMK-3 | D | D |
| Staurosporin | PKC/MLCK/PKA/PKG | D | D |
| Wortmannin | PI-3K | — | — |
| SB-202190/SB-203580 | SAPK2a/p38 and SAPK2b/p38β | D | D |
| PD98059 | MEK1 | D | — |
| Rapamycin | p70S6K, cdk2 | — | — |
| LY294002 | PI3-K | — | — |
| Anisomycin | SAPK2a/p38 and SAPK2b/p38b | In | In |
a
Based on results of Northern blot analysis of three independent experiments under each condition. The D and In are defined by 30% or more decrease or increase in reference to CSF-1 alone. −, No or insignificant effect.